Form 4: Alector Director Elizabeth Garofalo Granted Significant Equity Awards

Alector, Inc. Director Elizabeth A. Garofalo was granted 28,700 restricted stock units and options to purchase 9,450 shares of common stock, aligning her interests with shareholders.

Summary

• Elizabeth A. Garofalo, a Director of Alector, Inc. (ALEC), acquired 28,700 shares of common stock in the form of Restricted Stock Units (RSUs) on June 11, 2025, at a price of $0.00 per share.
• These RSUs will vest on the earlier of June 11, 2026, or the date of Alector's next annual meeting of stockholders.
• Additionally, Ms. Garofalo was granted stock options to acquire 9,450 shares of common stock on June 11, 2025, with an exercise price of $1.63 per share.
• The stock options will vest in 12 equal monthly installments beginning on July 11, 2025, or in full on the earlier of the one-year anniversary of the grant date or the date of the Issuer's next annual meeting of stockholders.
• Following these transactions, Ms. Garofalo beneficially owns 89,950 shares of common stock directly and 9,450 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The document reports a standard equity grant to a director, which is generally a positive sign of alignment between management and shareholders, and a routine compensation event. It does not contain any negative financial or operational news.

Positives

• The grant of restricted stock units and stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance and value creation.
• The vesting schedules for both RSUs and stock options encourage continued service and commitment from the director.

Future Outlook

The document details future vesting schedules for equity awards, indicating a continued commitment to long-term incentive plans for directors, aligning their future compensation with company performance.

Industry Context

This Form 4 filing reflects standard practice in the biotechnology and pharmaceutical industries, where equity compensation is a common tool to attract, retain, and incentivize key personnel, including directors, by linking their financial interests to the company's stock performance.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and stock options for director compensation is a common practice across publicly traded companies, particularly in the biotech sector, aligning with typical industry standards for executive and board remuneration.
• The vesting schedules, including time-based vesting and acceleration upon specific events like the annual meeting, are consistent with corporate governance best practices aimed at retaining talent and incentivizing long-term value creation.

Related Party Transactions

• The transaction involves the grant of equity awards to Elizabeth A. Garofalo, a Director of Alector, Inc., which constitutes a related party transaction as it is between the company and a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially leading to better long-term decision-making aimed at increasing shareholder value.
• Employees: While not directly impacting employees, such compensation practices for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The restricted stock units are scheduled to vest on the earlier of June 11, 2026, or the date of the Issuer's next annual meeting of stockholders.
• The stock options will begin vesting in 12 equal monthly installments starting July 11, 2025, or vest in full on the earlier of the one-year anniversary of the grant date or the date of the Issuer's next annual meeting of stockholders.

Key Dates

Recommendation

Keywords

Alector Inc., ALEC, Form 4, SEC filing, insider transaction, restricted stock units, RSUs, stock options, equity compensation, director compensation, beneficial ownership, corporate governance